Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06328686 · Emory University

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

What this study is about

This early phase I trial evaluates different administration techniques (taken by mouth or given through a vein (IV)) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid.

View original scientific description

This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid. Amino acids are the molecules that join together to form proteins in the body. Arginine supplementation has been shown to improve how brain metastases respond to radiation therapy. The optimal dosing of arginine for this purpose has not been determined. This study measures the level of arginine in the blood with oral and intravenous dosing at specific time intervals before and after drug administration to determine the best dosing strategy.

Interventions

DIETARY_SUPPLEMENT

Arginine

Given IV or PO

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Spectroscopy

Undergo spectroscopy

RADIATION

Whole-Brain Radiotherapy

Undergo WBRT

Primary outcome measures

Peak plasma L-arginine (arginine) and arginine metabolite concentration

Time frame: Within 4 hours of oral and intravenous (IV) dosing of L-arginine

By compartmental pharmacokinetic analysis, the plasma arginine levels at before administration, 10 min, 30 min, 1 hour, 2 hours, and 4 hours post administration will be used to estimate the median time to reach the peak plasma arginine and the mean value of peak. This will be done separately by two arms.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Diagnosis of brain metastases from any primary cancer
  • Planned to undergo whole-brain radiation therapy (Hippocampal avoidant is ok)
  • No systemic anti-neoplastic agent concurrent with WBRT (memantine is ok)
  • Not inpatient at the time of treatment start
  • Age 18 or older
  • Able to consent for self

Exclusion criteria

  • Patient unwilling/unable to receive daily arginine treatment (IV or oral) for the 10 days of WBRT
  • Systemic therapy continuing during WBRT
  • Creatinine \> 1.5 x the upper limit of normal
  • Alanine aminotransferase (ALT) \> 6x the upper limit of normal
  • Patient planned to be treated as an inpatient
  • Age \< 18 years
  • Adult not able to consent for self
  • Cognitively impaired/impaired decision-making capacity

Where

  • Atlanta, Georgia

Collaborators

National Cancer Institute (NCI)

Related conditions & keywords

Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Sep 17, 2025 · Source of record for eligibility and locations

📊
1 of 10 participants interested
10% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Atlanta

Georgia

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Essential Tremor Trials by City

Browse all essential tremor clinical trials in these cities — not just this study.

Looking for Metastatic Malignant Neoplasm in the Brain Treatment in Atlanta?

Join others in Georgia exploring innovative treatment options through clinical research

Metastatic Malignant Neoplasm in the Brain Treatment Options in Atlanta, Georgia

If you're searching for Metastatic Malignant Neoplasm in the Brain treatment in Atlanta, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Atlanta and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Metastatic Malignant Neoplasm in the Brain. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Georgia
Now Enrolling
Up to 10 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Metastatic Malignant Neoplasm in the Brain?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Metastatic Malignant Neoplasm in the Brain

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Metastatic Malignant Neoplasm in the Brain Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06328686. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.